Two frontiers define the outermost ambition of contemporary science: the cosmos above us and the genome within us. Both are being transformed by private investment, computational power, and a generation of researchers who grew up treating the impossible as a starting point.
Space has been democratised, or at least partially so. SpaceX's Falcon 9 — the first orbital rocket to consistently land its first stage for reuse — has reduced the cost of reaching low Earth orbit by approximately 80% compared to the Space Shuttle era. The Starship system, designed for full and rapid reusability, aims to bring costs down another order of magnitude, potentially opening Mars as an achievable destination within this decade. Blue Origin, Rocket Lab, and a growing cohort of launch providers are filling a market that simply did not exist twenty years ago.
The International Space Station is approaching retirement, and commercial successors are in development from Axiom Space and others. These stations are designed not as government science platforms but as commercial destinations for research, manufacturing, and eventually tourism. In microgravity, certain pharmaceutical crystals form with a purity impossible to achieve on Earth. Certain alloys and semiconductors behave differently. Space manufacturing is not science fiction — it is a near-term industrial strategy.
Biotechnology's revolution pivots on CRISPR-Cas9, the molecular editing system derived from bacterial immune mechanisms. Since Jennifer Doudna and Emmanuelle Charpentier's foundational 2012 paper — recognised with the 2020 Nobel Prize in Chemistry — CRISPR has been used to correct genetic defects causing sickle cell disease, develop cancer therapies that train the immune system to target tumours, and engineer crops resistant to drought and disease. The first CRISPR-based therapy, Casgevy, received regulatory approval in 2023 for sickle cell disease and beta-thalassemia — a landmark in the translation of gene editing from laboratory to clinic.
Synthetic biology extends these capabilities further, moving from editing existing genes to writing entirely new ones. Researchers have constructed minimal genomes from scratch, designed microorganisms that produce biofuels or break down plastic waste, and programmed cells to act as biological computers that respond to specific molecular signals. The cell itself is becoming programmable infrastructure.
The convergence of space and biology is generating its own category of research. Studying how microgravity affects cell behaviour, protein folding, and ageing processes has implications for medicine on Earth. Growing human tissue in microgravity environments may eventually yield organs for transplantation. The two frontiers, outer and inner, are beginning to inform each other in ways that neither field anticipated.